Toll-like receptor-5 (TLR5) signaling regulates the immune privileged status of the liver and is involved in hepatic immune disorders. However, the role of TLR5 has not yet been investigated in experimental models of concanavalin A (Con A)-mediated liver injury. Here, we show that TLR5 is highly up-regulated in the hepatic mononuclear cells of mice during Con A-induced hepatitis. Increased mortality and liver histopathology of TLR5-deficient mice correlated with excessive production of proinflammatory cytokines, suggesting that TLR5 knockout mice were more susceptible to Con A-induced hepatitis. We also report that administration of CBLB502, an exogenous TLR5 agonist, substantially alleviated Con A-mediated hepatitis in wild-type mice as shown by increased survival rates, reduced aminotransferase and proinflammatory cytokine production, impaired lymphocyte infiltration, and ameliorated hepatocyte necrosis and/or apoptosis. Mechanistic studies revealed that CBLB502 acts as a negative regulator in limiting T-cell/natural killer T-cell activity and cytokine production in the Con A-hepatitis model. Bone marrow transplantation experiments showed that TLR5 in bone marrow-derived cells contributed to the hepatoprotective efficacy of CBLB502 against Con A-induced liver injury. Moreover, interleukin-6 elevation induced by CBLB502 is an important protective factor against Con A-induced liver injury.
T he toll-like receptors (TLRs) are a family of ligand-binding molecules that engage a variety of microbial products and play an important role in inflammatory responses.
(1) An increasing number of studies have demonstrated that TLR signaling is involved in the pathophysiology of human hepatic disease. (2) Signaling through TLR2, (3) TLR3, (4) TLR4, (5) and TLR9 (6) has also been reported to contribute to concanavalin A (Con A)-induced liver injury. (7) Indeed, pretreatment with the TLR4 agonist lipopolysaccharide (LPS) provides protection against Con A-induced hepatitis through induction of interleukin-6 (IL-6). (8) The role of TLR3 in the Con A model was confirmed in TLR3 knockout mice, which are protected from Con A-induced liver injury. (4) In contrast, pretreatment with the TLR3 agonist polyinosinic:polycytidylic acid has been reported to protect mice against Con A-mediated liver injury through down-regulation of T cells/natural killer T (NKT) cells. (9) TLR9 activation by CpG oligodeoxynucleotides aggravated Con A-induced hepatitis, (6) but Zhang et al. showed that pretreatment with a different CpG oligodeoxynucleotide sequence attenuated Con A-induced liver damage. (10) Thus, the role of the TLRs in the Con A hepatitis model is controversial, and further studies are required to clarify the contribution of specific TLRs to immune-mediated hepatitis induction.
TLR5 is expressed in a broad range of cell types, and its agonist has diverse immunomodulatory effects on both innate and adaptive immunity in mice and humans. (1) Accumulating studies have demonstrated that using flagellin (a TLR5 agonist) as an adjuvant can promote cytokine production, trigger a generalized recruitment of lymphocytes to secondary lymphoid sites, and activate TLR5
1 cluster of differentiation 11c-positive (CD11c 1 ) cells and T lymphocytes. (11, 12) Mice lacking TLR5 displayed spontaneous colitis, metabolic syndrome, and enhanced susceptibility to several in vivo infection models, (13, 14) indicating that a TLR5-mediated mechanism plays a critical role in regulating the immune response. TLR5 signaling was shown to be extensively involved in the occurrence of human inflammatory diseases. (15) Activation of TLR5 signaling by CBLB502, a pharmacologically optimized flagellin derivative, inhibits tumor growth and protects mammals from radiation and ischemia-reperfusion injuries. (16, 17) TLR5 signaling also regulates the immune privileged status of the liver and is activated in hepatic immune disorders. Overactivation of TLR5 signaling by highdose flagellin caused acute inflammatory responses in the liver. (12) Recently, it was shown that the liver is the key target organ of CBLB502-dependent TLR5 signaling activity in vivo, (18) and TLR5 stimulation by CBLB502 rescued mice from hepatotoxicity induced by Fas, (18) an essential transducer of the cell death signal in many inflammatory liver diseases. (19) These results indicated that TLR5 signaling may protect the liver from severe stresses. Moreover, administration of CBLB502 promoted NK cell-mediated anticytomegalovirus immunity in mice and resulted in significantly reduced liver viral load and optimal protection from mouse cytomegalovirus lethality. (20) Several studies have also indicated that TLR5 signaling serves as a negative regulator in limiting immune cell activation and cytokine production. NKT cells preactivated by flagellin displayed hyporesponsiveness toward a-galactosylceramide (a-Galcer) or Con A restimulation 3 weeks later, (21) thereby demonstrating the unique role of TLR5 signaling in modulating the activity of NKT cells, a critical cell type that has been extensively implicated in the pathogenesis of inflammatory human diseases. The TLR5 agonist flagellin B has been shown to inhibit the function of T helper 2 (Th2)-like and Th17-like NKT cells in patients with asthma. (22) Moreover, flagellin has immunosuppressive roles by activating recipient regulatory T cells (Tregs), (23) suggesting a potent immune tolerance application of the TLR5 agonist. For example, administration of flagellin could attenuate graft-versus-host disease and reduce proinflammatory cytokines produced by activated donor T cells in an allogeneic bone marrow (BM) transplantation model. (24) These findings support the diverse functions of TLR5 under different physiological and pathological conditions. To our knowledge, the functional role of TLR5 has not yet been investigated in experimental models of T cell-mediated liver injury.
In the present study, we showed that TLR5 knockout mice were more susceptible to Con A-induced hepatitis and that the exogenous TLR5 agonist CBLB502 severely impaired Con A-mediated hepatitis. Our results provide insight into liver pathophysiology and offer new opportunities to develop future therapeutic strategies for hepatic immune disease.
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Materials and Methods
ANIMALS
Specific pathogen-free C57BL/6 mice were purchased from the Vital River Experimental Animal Company (Beijing, China); TLR5 -/-mice on a C57BL/6 background from Jackson Laboratory were kindly provided by Prof. Huimin Yan (Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China). MyD88 -/-mice were a kind gift from Dr. Shizuo Akria (Hyogo College of Medicine, Hyogo, Japan). All animals were maintained in a temperature-controlled, specific pathogen-free room with a 12-hour light and dark cycle and ad libitum diet (standard laboratory chow and water) in the Experimental Animal Center of the Academy of Military Medical Sciences according to the National Laboratory Animal guidelines (Ministry of Health, P.R. China, 1998). All mice used in the experiments were 6-9 weeks of age. The mouse protocols were approved by the Beijing Institute of Radiation Medicine (Beijing, China) Animal Care and Use Committee.
ACUTE LIVER INJURY
Con A-induced acute liver injury was performed in mice as reported. (7) Briefly, mice were injected intravenously with Con A (Sigma, St. Louis, MO) dissolved in pyrogen-free phosphate-buffered saline (PBS) at various doses from 12 mg/kg to 25 mg/kg in different experiments as indicated in the figure legends. To induce NKT cell-dependent hepatitis, (25) mice were intravenously administered a-Galcer (Enzo Life Sciences, Farmingdale, NY) dissolved in PBS containing 0.5% Tween-20 at a dose of 0.2 lg/mouse to 2 lg/ mouse with or without D-galactosamine (D-Gal; 700 mg/kg body weight) pretreatment. In some experiments, mice were intraperitoneally injected with DGal (700 mg/kg body weight) and LPS (50 lg/kg body weight) to induce fulminant hepatitis.
DETECTION OF INFLAMMATORY CYTOKINE AND CHEMOKINE LEVELS
Serum IL-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha (TNF-a), interferon-gamma (IFN-c), macrophage inflammatory protein-1a, IL-17A, and keratinocyte chemoattractant levels were measured using a BD Cytometric Bead Array (BD Bioscience, San Diego, CA) according to the manufacturer's instructions. Fluorescence-activated cell sorting analysis was performed using a BD FACSCalibur instrument (BD Bioscience), and cytokine concentrations were calculated using FCAP Array software (version V1.0.1).
FLOW CYTOMETRY AND INTRACELLULAR CYTOKINE STAINING
Liver mononuclear cells (MNCs) were obtained by density centrifugation with Percoll (GE Healthcare, Uppsala, Sweden) as described in the Supporting Information. For cell surface staining, isolated liver MNCs were incubated with fluorescein isothiocyanate, phycoerythrin (PE), PercpCy5.5 and allophycocyanin-labeled anti-CD3e (145-2C11), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD69 (H1.2F3), anti-CD25 (PC61.5), anti-NK1.1 (PK136), anti-CD11b (M1/70), antiCD11c (N418), anti-F4/80 (BM8), and anti-Gr-1 (RB6-8C5) antibodies (eBioscience, San Diego, CA). For extracellular TLR5 detection, liver MNCs were stained with PE-labled anti-TLR5 (ACT5) antibody or isotype immunoglobulin G (IgG; BD Bioscience). For intracellular antigen detection, cells were first stained with membrane marker antibodies, fixed and permeablized, and then stained with intracellular antibodies, including PE-labeled anti-IL-4 (11B11), allophycocyanin-labeled anti-TNF-a (MP6-XT22), and PE-labeled anti-IFN-c (XMG1.2) antibodies (Biolegend, San Diego, CA). Stained cells were analyzed using a BD FACSCalibur instrument (BD Bioscience) and FlowJo software (Tree Star, Ashland, OR).
IN VIVO NEUTRALIZATION OF ENDOGENOUS IL-6
One hour prior to CBLB502 administration, mice were intraperitoneally injected with rat antimouse IL-6 monoclonal antibody (MAb; 500 lg/mouse) or rat IgG isotype (500 lg/mouse; both from R&D Systems). Serum or liver tissues were collected 3 or 12 hours, respectively, after Con A hepatitis induction.
STATISTICAL ANALYSIS
All data are expressed as the mean 6 standard deviation and were analyzed using unpaired Student t tests. Differences were considered significant when P < 0.05. Animal survival curves were compared using Kaplan-Meier analysis, and differences were considered significant when P < 0.05. All statistical analyses were carried out using GraphPad Prism 5 (GraphPad Software, San Diego, CA).
Results
TLR5 -/-MICE DEVELOPED SIGNIFICANTLY MORE SEVERE CON A-INDUCED HEPATITIS
To eliminate the effect of intestinal pathogenic bacteria on Con A-induced liver injury, (13) age-matched and sex-matched TLR5 -/-and wild-type (WT) littermates were treated with gentamycin for 1 week before Con A injection to deplete gram-negative, gut-derived bacteria. All mice appeared generally healthy, and analysis of the small intestine did not reveal gross phenotypic alterations (data not shown). A 16S ribosomal RNA gene-based microbiota sequencing analysis showed that microbial composition was similar between WT mice and TLR5 -/-mice (Supporting Fig. S1 ). To assess the role of the TLR5 signaling pathway in Con A-induced liver damage, we administered different doses of Con A to WT and TLR5 -/-and WT mice. n 5 3-5 for each time point per group. Data are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. (E) Liver tissues from TLR5 -/-and WT hepatitis mice were collected 1 hour after Con A (12 mg/kg) challenge, and liver lymphocytes were stained with anti-CD3, anti-TNF-a, and anti-IFN-c antibodies to determine the percent of cytokine-producing CD3 1 T cells. n 5 6. Data are representative of two independent experiments. ***P < 0.001. (F) Numbers of liver MNCs harvested before or 12 hours after Con A (12 mg/kg) exposure. n 5 4-5 for each group. Data are representative of at least two independent experiments. *P < 0.05. Abbreviation: N.S., not significant.
lethal in TLR5
-/-mice but not in WT mice, but a lower dose (12 mg/kg body weight) only induced severe hepatitis in both WT and TLR5 -/-mice. Thus, all of the following experiments were performed using these doses. Con A (15 mg/kg) injection resulted in lethality for 75% of the TLR5 -/-mice, whereas all WT mice survived until 72 hours after Con A administration (Fig. 1A) . Twelve hours after 12 mg/kg Con A injection, serum alanine aminotransferase (ALT) levels were significantly higher in TLR5 -/-mice compared to WT mice (Fig. 1B) . These findings were correlated with the histopathological results, which clearly indicated more massive necrosis in the liver tissues of TLR5 -/-mice (Fig. 1C) . Serum IL-2, IL-4, IL-6, TNF-a, IFN-c, and IL-17A levels were much higher in TLR5
-/-mice after Con A injection (Fig. 1D ). Intracellular staining of liver MNCs revealed a significantly higher percentage of TNF-a-producing and IFN-c-producing CD3
1 cells in TLR5 -/-mice compared with control mice ( Fig. 1E ; Supporting Fig. S2 ). Moreover, the number of liver-infiltrating MNCs in TLR5 -/-mice was significantly higher than that in WT mice (Fig. 1F ). These data suggest that TLR5 -/-mice are more susceptible to Con A-induced hepatitis.
THE TLR5 AGONIST CBLB502 PROTECTS MICE FROM CON A-INDUCED HEPATITIS
To further elucidate the role of TLR5 signaling in immune-mediated hepatitis, we investigated whether administration of CBLB502 inhibits Con A-induced liver injury in WT mice. After injection of a nonlethal dose of Con A (15 mg/kg), a significant increase in serum ALT was observed; however, administration of CBLB502 12 hours prior to Con A injection suppressed the increased ALT in a dose-dependent manner ( Fig. 2A) . Additionally, a single dose of CBLB502 completely protected mice from a 25 mg/kg Con A challenge (Fig. 2B) , a dose previously reported as lethal in WT mice. (9, 10) Notably, when CBLB502 was injected after onset of hepatitis (0.5 hours after Con A challenge), 77% of the Con A-treated mice survived (Supporting Fig. S3 ), indicating the prophylactic and therapeutic effects of CBLB502 on immune-mediated hepatitis.
Histological examination revealed large necroinflammatory areas in the liver after Con A exposure, while pretreatment with CBLB502 significantly suppressed this pathological process, and almost no necrosis was detected in the CBLB502-pretreated group 12 hours and 24 hours after Con A injection (Fig. 2C ). Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling showed massive hepatocyte apoptosis in non-necrotic liver tissues of Con A-treated animals, while this phenomenon was significantly mitigated in CBLB502-pretreated animals (Supporting Fig. S4A ). Moreover, activation of caspase-3 and caspase-8 in the liver tissues of Con Atreated mice was diminished by CBLB502 treatment (Supporting Fig. S4B ). These results indicated that preactivation of TLR5 signaling could protect against Con A-mediated hepatic damage.
To determine whether the protection afforded by CBLB502 required TLR5, WT and TLR5 -/-mice were pretreated with CBLB502 and then injected with Con A 12 hours later. The results showed that mice lacking TLR5 were not protected from liver injury as determined by inflammatory cytokines (Supporting Fig. S5A ), serum aminotransferase measurements (Supporting Fig. S5B ), and histological analysis (Supporting Fig. S5C,D) . Importantly, we verified that TLR5 -/-mice could still be protected after the Con A challenge by the TLR4 agonist LPS (Supporting Fig.  S5B-D) . The severity of hepatitis induced by Con A was significantly lower in MyD88 -/-mice than in WT mice; however, CBLB502 failed to ameliorate the hepatic injury induced by Con A in MyD88 -/-mice as determined by histopathology and serum ALT levels (Fig. 2D) , indicating that attenuation of Con Ainduced hepatitis by CBLB502 requires the TLR5/ nuclear factor kappa B (NF-jB) signaling pathway.
CBLB502 PRETREATMENT REDUCES INFILTRATION OF MULTIPLE LINEAGES OF LYMPHOCYTES IN CON A-INDUCED HEPATITIS
To determine whether CBLB502-pretreated mice showed altered recruitment of immune effective cells into the liver, (26) we quantitated the number of MNCs in the livers of PBS-treated and CBLB502-treated mice after Con A challenge. CBLB502 pretreatment significantly reduced the Con A-induced increase in total MNCs in the liver compared with the PBS vehicle, although CBLB502 pretreatment did not promote lymphocyte apoptosis after Con A injection ( Fig. 2E;  Supporting Fig. S6 ). We also calculated the number of different lymphocyte subsets in the liver of CBLB502-treated and PBS-treated mice after Con A injection.
CBLB502 pretreatment significantly reduced the number of intrahepatic CD3 Fig. S7 ). The impaired infiltration of neutrophils in the liver of CBLB502-pretreated mice was also confirmed by immunohistochemical assays (Supporting Fig. S8A ) and myeloperoxidase quantification 12 hours after Con A injection (Supporting Fig. S8B ). Significant defects in the serum CD4
1 T-cell chemoattractant macrophage inflammatory protein-1a and the neutrophil chemoattractant keratinocyte chemoattractant induced by Con A were observed in CBLB502-pretreated mice (Fig. 2F) . The paucity of intrahepatic leukocyte infiltration in the CBLB502 pretreatment group was also verified by a quantitative real-time assay, which showed significant decreases in hepatic mRNA expression levels of intercellular adhesion molecule-1 and chemokine (C-X-C motif) ligand 10 (Supporting Fig. S9 ), two essential mediators Liver tissues from CBLB502-pretreated or PBS-pretreated mice were collected at various time points as indicated after Con A (15 mg/kg) challenge for hematoxylin and eosin staining (original magnification 3 100). Black arrows refer to necrotic area. Data are representative of at least two independent experiments. (D) Serum ALT levels and liver hematoxylin and eosin staining (original magnification 3 100) in CBLB502-pretreated or PBS-pretreated WT and MyD88 -/-mice 12 hours after Con A (15 mg/kg) challenge. n 5 3-4 per group. Data are representative of two independent experiments. **P < 0.01, ***P < 0.001. (E) Hepatic MNC counts before or 12 hours after Con A (15 mg/kg) exposure. n 5 4-5 per group. Data are representative of at least two independent experiments. **P < 0.01. (E) Levels of chemoattractants (macrophage inflammatory protein-1a and keratinocyte chemoattractant) in serum of CBLB502-pretreated or PBS-pretreated mice 3 hours after Con A (15 mg/kg) challenge. n 5 5 per group. Data are representative of two independent experiments. **P < 0.01. Abbreviations: KC, keratinocyte chemoattractant; MIP-1a, macrophage inflammatory protein-1a; N.S., not significant. implicated in leukocyte recruitment in inflammatory liver diseases. (26) The percentage of hepatic Tregs (Foxp3
1 ) was statistically higher in livers of CBLB502-pretreated mice compared to PBS controls (Supporting Fig. S10A,B) . To identify the potential factors that may contribute to Treg generation, IL-10 and transforming growth factor-b levels in liver tissues were detected by real-time assays, and the results showed that IL-10 and transforming growth factor-b were significantly elevated at the mRNA level in liver tissues from CBLB502-pretreated mice compared to the control group (Supporting Fig. S10C ). These results are consistent with previous reports that the expression of transforming growth factor-b and IL-10 was increased in flagellin-treated hosts compared to controls. (27) To define the functional role of Tregs in CBLB502-protected, Con A-induced hepatitis, we depleted CD25
1 cells in CBLB502-pretreated mice by injecting anti-CD25 MAbs; the results showed that mice depleted of CD25 1 cells were still protected from liver injury by CBLB502 injection (Supporting Fig. S10D,E) , suggesting that the increased number of Tregs induced by CBLB502 did not play a key role in protection against Con Ainduced liver injury.
CBLB502 PRETREATMENT INHIBITS PROINFLAMMATORY CYTOKINE PRODUCTION AFTER CON A INJECTION
We then investigated whether treatment of mice with CBLB502 affects the production of proinflammatory cytokines by Con A administration. Injection of CBLB502 alone in WT mice induced rapid increases in serum proinflammatory cytokines, such as IL-6, IL-10, TNF-a, and IFN-c; but the increase was transient and normalized 12 hours after injection of CBLB502 (Supporting Fig. S11 ). In addition, we found that injection of CBLB502 by itself induced expression of several major inflammatory mediators, including monocyte chemoattractant protein-1, keratinocyte chemoattractant, and secretory interleukin-1 receptor antagonist (Supporting Fig. S11 ). Levels of IL-2, IL-4, IL-6, TNF-a, and IFN-c were significantly lower in CBLB502-treated mice compared with PBS controls from 1 to 12 hours after Con A injection (Fig. 3A) . Additionally, administration of CBLB502 resulted in significant decreases in hepatic protein levels of IL-2, IL-4, IL-6, TNF-a, and IFN-c from 3 to 12 hours post-Con A injection (Fig. 3B) . These results indicate that CBLB502 protection may be mediated by inhibiting inflammatory immune cell-derived cytokine release induced by Con A.
SUPPRESSION OF HEPATIC T/NKT CELLS IN CON A-INDUCED HEPATITIS BY CBLB502 PRETREATMENT
We investigated whether the TLR5-mediated mechanism had inhibitory effects on hepatic immune effective cells. The absolute quantity of the intrahepatic lymphocyte population displayed significant reduction in activated CD4
1 T-cell infiltration after Con A injection, which was accompanied by lower levels of the mean fluorescence intensity of CD69 1 and CD25 1 in CD4 1 T cells from CBLB502-pretreated mice (Fig. 4A,B) . Moreover, the CBLB502-pretreated Con A group exhibited a significant decrease in IL-4 1 , TNF-a 1 , and IFN-c 1 in hepatic T cells compared with the control group ( Fig. 4C; Supporting Fig. S13 ). NKT cells rapidly disappeared after Con A exposure, (28) while a moderate but still statistically significant attenuation of NKT reduction was observed in CBLB502-treated Con A hepatitis mice (Fig. 4D) . 
NK1
.1 -) cells from CBLB502-pretreated or PBS-pretreated mice at 1 hour after Con A (15 mg/kg) challenge. n 5 5. Data are representative of at least two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Percent of hepatic NKT cell in CBLB502-pretreated or PBS-pretreated mice at indicated time points post-Con A (15 mg/kg) challenge. Data are representative of two independent experiments. *P < 0.05. (E) Expression of Fas ligand and CD40 ligand in hepatic NKT cell in CBLB502-pretreated or PBS-pretreated mice at 1.5 hours post-Con A (15 mg/kg) challenge. Data are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: MFI, mean fluorescence intensity; N.S., not significant. ligand in NKT cells was detected, and the results showed that CBLB502 pretreatment could inhibit Con A-mediated expression of Fas ligand and CD40 ligand in NKT cells ( Fig. 4E; Supporting Fig. S12A ). The down-expression of TNF-related apoptosisinducing ligand (CD253) and CD40 ligand in NKT cells of CBLB502-treated mice was also verified by real-time PCR (Supporting Fig. S12B ). Additionally, compared with PBS controls, CBLB502-pretreated mice displayed significantly lower percentages of IL-4-producing, TNF-a-producing, and IFN-c-producing NKT cells ( Fig. 4C; Supporting Fig. S13 ) and IFN-cproducing CD8 1 T cells (Supporting Fig. S14 ). These results suggest that T/NKT-cell activation was attenuated in the liver of the CBLB502-treated Con A-induced hepatitis model.
CBLB502-MEDIATED HEPATOPROTECTIVE EFFECTS REQUIRE TLR5 SIGNALING IN HEMATOPOIETIC CELLS
To explore the mechanism of hepatic Con A injury prevention, we first determined the expression of TLR5 in liver tissues by western blotting. The results showed that liver tissues express low levels of TLR5, which were increased 12 hours after Con A -/-to TLR5 -/-, and TLR5 -/-to WT) were exposed to Con A (12 mg/kg) with or without CBLB502 pretreatment (12 hours prior to Con A). (C) Liver tissue histopathology (magnification 3 100) and (D) percentages of necrotic area were determined at 12 hours after Con A injection as indicated. Black arrows show necrotic areas. n 5 4-5 per group. Data are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; N.S., not significant. administration (Fig. 5A) . To determine which cell compartments express TLR5, the expression of TLR5 in hepatic MNCs and primary hepatocytes was detected by flow cytometry. The antibody specificity was verified using BM cells from TLR5 -/-mice (Supporting Fig. S15A ). No TLR5 expression was detected in mouse primary hepatocytes before or after Con A administration at 12 hours (Supporting Fig. S15B ). However, TLR5 expression was detected in hepatic MNCs and increased 12 hours after Con A injection. Moreover, TLR5 expression was detected in various subsets of liver MNCs, including neutrophils and NKT cells, and up-regulated after Con A injection in WT mice (Fig. 5B) . Furthermore, expression of TLR5 in NKT cells was verified by RT-PCR (Supporting Fig. S16 ). These findings indicated a limited role of hepatocytes in protecting against Con A hepatitis in CBLB502-pretreated mice.
To address this hypothesis, BM-reconstituted chimeric mice were generated between WT and TLR5 -/-mice, and four types of BM chimeric mice (WT to WT, WT to TLR5 -/-, TLR5 -/-to TLR5 -/-, and TLR5 -/-to WT) were produced. After full BM engraftment was confirmed (data not shown), Con Ainduced hepatitis was studied in the chimeric mice 10 weeks after BM transplantation. A 12 mg/kg Con A injection resulted in lethality for 2/5 of the TLR5 -/-to TLR5 -/-mice and TLR5 -/-to WT mice, indicating more serious hepatitis in these mice. Histological analysis showed that the TLR5 -/-to WT and TLR5 -/-to TLR5 -/-BM chimeric mice displayed more massive necrosis in the liver tissues after Con A challenge, whereas significantly attenuated liver injury was observed in WT to TLR5 -/-BM chimeric mice compared with that in TLR5 -/-to TLR5 -/-BM chimeric mice (Fig. 5C, 5D ). These results indicate that functional TLR5 in hematopoietic cells is important in Con A-induced liver damage. Consistent with the previous results, WT to WT BM chimeric mice receiving CBLB502 pretreatment exhibited substantially attenuated hepatic injury induced by Con A, whereas CBLB502 injection in TLR5 -/-to TLR5 BM chimeras failed to ameliorate the hepatitis. Notably, CBLB502 pretreatment did not protect TLR5 -/-to WT BM chimeric mice from Con A hepatitis (Fig.  5C,D) , indicating that TLR5 in hematopoietic cells plays a key role in CBLB502 protection against Con A-induced fulminant hepatitis.
IL-6 INDUCTION CONTRIBUTED TO THE PROTECTION AGAINST LIVER INJURY IN CBLB502-PRETREATED MICE
The role of IL-6 in preventing Con A-induced liver injury has been well documented. (29) CBLB502 injection alone significantly induced IL-6 expression ( Fig.  6A; Supporting Fig. S11 ) and subsequent signal transducer and activator of transcription-3 phosphorylation in liver tissues (Fig. 6A) . Specifically, monocytes/macrophages are probably the main producer of endogenous IL-6 induced by CBLB502 as hepatic macrophages constitutively express TLR5 and in vivo depletion of monocytes/macrophages by clodronateliposome results in almost 80% reduction of the serum IL-6 level 1 hour after CBLB502 administration (Supporting Fig. S17A-C) . To evaluate the role of IL-6 in protection against Con A hepatitis in CBLB502-pretreated mice, we neutralized IL-6 using anti-IL-6 MAbs (500 lg/mouse) 1 hour before CBLB502 injection and then challenged the mice with Con A 12 hours later. IL-6 neutralization prior to CBLB502 injection significantly reduced the hepatic protective potency of CBLB502, which was associated with increased serum proinflammatory cytokine (Fig. 6B ) and ALT levels (Fig. 6C) . Histological analysis also revealed that passive blockage of endogenous IL-6 resulted in mild necrosis in liver tissues compared to isotype controls (Fig. 6D) . Furthermore, we found that TLR5 -/-mice pretreated with IL-6 were protected against Con A-induced hepatitis, as shown by the serum ALT level (Fig. 6E) . These results confirmed that CBLB502-induced IL-6 production is an important component of protection against Con A-induced liver injury. In addition, we found that IL-6 pretreatment in TLR5 -/-mice or WT mice did not significantly increase the percentage of hepatic Tregs compared to PBS controls after Con A injection (Supporting Fig.  S18 ). These results are consistent with previous reports indicating that the levels of Tregs were not elevated by in vivo or in vitro IL-6 treatment. (29) IL-10 has been reported to protect mice from Con A-induced hepatic injury. (30) To evaluate the role of IL-10 induced by CBLB502, IL-10 was neutralized using anti-IL-10 MAbs. The results showed that IL-10 neutralization prior to CBLB502 injection did not affect the protective effect of CBLB502 (Supporting Fig. S19 ), indicating that CBLB502-induced IL10 expression did not contribute to protection against Con A hepatitis. Injection of CBLB502 by itself did not induce IL-4 expression (Supporting Fig. S11 ), but CBLB502 pretreatment significantly decreased mouse serum IL-4 after Con A injection, as described (Fig. 3A) . To determine the pathological role of decreasing IL-4, exogenous recombinant IL-4 was injected 1 hour before Con-A injection, and the results showed significant hepatitis in IL-4-injected mice. When exogenous recombinant IL-4 was injected after CBLB502 pretreatment, the protective effect of CBLB502 pretreatment was not affected (Supporting Fig. S20 ), suggesting that inhibition of IL-4 expression may not be a key mediator in the CBLB502 protection against Con A hepatitis.
CBLB502 SUPPRESSES NKT CELL-DEPENDENT INFLAMMATORY LIVER INJURY
The TLR5 signaling pathway is involved in regulation of NKT-cell function, (21, 22) and NKT cells are key cytotoxicity effectors in Con A-induced hepatitis (28) ; therefore, we elucidated the role of CBLB502 in modulating the activity of NKT cells using an aGalcer-induced liver injury model. (25) CBLB502 inhibited a-Galcer-induced liver injury and reduced serum ALT (Fig. 7A) , IL-4, TNF-a, and IFN-c (Fig.  7B ) levels after a-Galcer injection. CBLB502 pretreatment also completely protected WT mice from aGalcer-induced death after D-Gal sensitization, and this protective effect was TLR5-dependent as CBLB502 failed to rescue any of the TLR5 -/-mice from the combined challenge of a-Galcer and D-Gal (Fig. 7C) . In contrast, CBLB502 pretreatment did not rescue mice from the D-Gal and LPS challenge (Supporting Fig. S21 ). Moreover, intracellular stain analysis revealed much lower rates of IL-4-producing, TNF-aproducing, and IFN-c-producing lymphocytes in CBLB502-pretreated mice compared to PBS controls (Fig. 7D) . Importantly, only the IL-4-producing, TNF-a-producing, and IFN-c-producing NKT, but not T cells displayed a significant decrease in CBLB502-pretreated animals ( Fig. 7E; Supporting  Fig. S22 ). Therefore, NKT cells are likely the key cell type targeted by CBLB502 in this immune-mediated hepatitis.
Discussion
In this study, we demonstrated the role of TLR5 in a Con A-induced hepatitis model. We found that loss of TLR5 resulted in higher sensitivity to Con Ainduced hepatitis and that activation of TLR5 signaling by CBLB502 significantly attenuated the Con Amediated liver injury. These data suggest that the TLR5 signaling pathway is critically involved in the pathogenesis of Con A-induced liver damage. Mechanistic studies revealed that CBLB502 functions as a FIG. 7 . CBLB502 suppresses NKT cell-dependent inflammatory liver injury. (A) Serum ALT levels of CBLB502-pretreated and PBS-pretreated mice at 12 hours after a-Galcer (2 lg/mouse) challenge. Data are representative of two independent experiments. *P < 0.05. (B) Levels of serum proinflammatory cytokine (IL-4, TNF-a, and IFN-c) in CBLB502-pretreated or PBS-pretreated mice at 2 hours after a-Galcer (0.2 lg/mouse) injection. Data are representative of two independent experiments. *P < 0.05, ***P < 0.001. (C) Survival curve of CBLB502-pretreated and PBS-pretreated D-Gal/a-Galcer (D-Gal, 700 mg/kg; a-Galcer, 0.2 lg/mouse) hepatitis WT and TLR5 -/-mice. n 5 10 for each group. (D) Liver tissues from CBLB502-pretreated or PBS-pretreated hepatitis mice were collected 2 hours after a-Galcer (0.2 lg/mouse) challenge, and the percentages of IL-4-positive, TNF-a-positive, and IFN-c-positive lymphocytes were analyzed by flow cytometry. n 5 6. Data are representative of two independent experiments. *P < 0.05, **P < 0.01. (E) IL-4-producing, TNF-a-producing, and IFN-c-producing liver lymphocytes were stained with anti-CD3 and anti-NK1.1 antibodies to show the cell type that these cytokines originated from. n 5 6. Data are representative of two independent experiments. *P < 0.05, **P < 0.01. negative regulator in limiting T/NKT-cell activity and cytokine production in the Con A-induced liver injury model. We also demonstrated that TLR5 expression in BM-derived cells contributed to liver injury after Con A injection and played a key role in the effects of CBLB502 against Con A-induced hepatitis. Our results showed that IL-6 induced by CBLB502 is an important protective factor against Con A-induced liver injury.
CBLB502 has been reported to have strong protective effects in several mouse disease models. (16) (17) (18) 31) The protective mechanism of CBLB502 involves TLR5-dependent NF-jB-mediated induction of multiple factors, including antiapoptotic proteins, scavengers of reactive oxygen species, cytokines, and antiinflammatory agents. (16) (17) (18) Recently, the liver has been described as one of the major organs responding to CBLB502 in vivo, and CBLB502 pretreatment completely protected mice from anti-Fas antibodyinduced fulminant liver injury by increasing hepatocyte resistance. (18) Moreover, there is evidence that CBLB502 directly stimulated NF-jB activity in hepatocytes. (18) Although our results indicated that the attenuated Con A-induced hepatitis in CBLB502-pretreated mice required the MyD88/NF-jB signaling pathway, it appears unlikely that directly stimulating NF-jB activation in hepatocytes by CBLB502 had this protective effect because we failed to detect TLR5 expression on freshly isolated mouse hepatocytes before or after Con A injection. These results were consistent with previous studies showing that primary cultured hepatocytes only respond to TLR2 and TLR 4 ligands. (32) Furthermore, using BM-reconstituted chimeric mice, we clearly showed that it was hematopoietic cells, and not nonhematopoietic cells, that contributed to the hepatoprotection provided by CBLB502 after Con A challenge as transplantation of TLR5 -/-BM cells to WT recipients completely abolished the efficacy of CBLB502. Moreover, in contrast to Fas-mediated caspase-dependent hepatotoxicity, Con A-induced hepatitis is independent of caspase activation and considered to be the result of concurrent effects of multiple immunological cells. These data implied that the protective mechanism of CBLB502 varies in different disease models.
In this study, a marked decrease in inflammatory immunological cell infiltration as well as systemic and liver-specific IL-4, IL-6, TNF-a, and IFN-c production were detected in CBLB502-pretreated mice; IL-2, a T lymphocyte-restricted cytokine that was considered to be a marker of Con A-induced T-cell activation in vivo, (7) also showed similar decreases. Moreover, intracellular staining revealed that CBLB502-pretreated mice exhibited significant decreases in IL4 1 , TNF-a 1 , and IFN-c 1 hepatic T cells compared with PBS-treated mice. These observations were consistent with the flow-cytometric results that clearly indicated down-regulation of the T-cell activation markers CD69 and CD25 on conventional CD4
1 T cells, indicating that CBLB502-induced responses may control the progression of Con A hepatitis through T cell-suppressive mechanisms. Studies have shown that NKT cells play a critical role in the process of Con A-induced hepatic injury. (28) Hepatic NKT-cell activation in Con A-induced hepatitis was characterized by rapid NKT-cell reduction. (28) Our results showed that down-regulation of NKT cells was partially impaired in the CBLB502-treated Con A group and accompanied by reduced IL-4-producing, TNF-a-producing, and IFN-cproducing NKT cells. In addition, direct activation of NKT cells by a-Galcer administration induced systemic production and intracellular production of IL-4, TNF-a, and IFN-c in NKT cells, which were significantly suppressed in CBLB502-pretreated animals. Importantly, CBLB502 completely rescued D-Galsensitized mice from a-Galcer-induced lethality in a TLR5-dependent manner. These results strongly suggested that inhibiting NKT-cell activation and subsequent proinflammatory cytokine release might play a key role in the CBLB502 protection of mice from immune-mediated hepatitis. This conclusion was consistent with previous studies, which demonstrated that long-term flagellin exposure was capable of inducing NKT-cell anergy. (21) Moreover, the TLR5 agonist flagellin B displayed optimal suppressive activities on NKT cell-mediated Th1-like, Th2-like, and Th17-like responses by inducing regulatory dendritic cells and T cells in experimental asthma mice or patients with asthma. (22) Tregs expressed high levels of TLR5 mRNA, and treatment of Tregs with flagellin was reported to enhance the regulatory activity of these cells. (23) We found that CBLB502 pretreatment increased CD4
1
CD25
1
FoxP3
1 Tregs in the liver, which has been shown to suppress immune responses and to be involved in protection of Con A-induced hepatitis. (33) Taken together, these data suggested that suppression of Con A-mediated immune responses was involved in CBLB502 protection from Con A-induced hepatitis and that the ability to modulate T-cell and NKT-cell function may allow CBLB502 to prevent or mitigate inflammatory liver diseases.
Induction of IL-6 by CBLB502 plays a key role in the drug's ability to protect mice against radiation injury and 5-fluorouracil toxicity.
(31) IL-6 was also reported to inhibit Con A-induced hepatitis. (29) In addition, similar to the protective effects of CBLB502 against T cell-mediated hepatitis, pretreatment with the TLR4 agonist LPS also provided protection against Con A through induction of IL-6. (8) Our results showed that IL-6 neutralization before CBLB502 injection resulted in significant reduction of the hepatic protective potency of CBLB502, indicating that induced elevation of IL-6 levels is one of the important factors of CBLB502 protection against Con A-induced liver injury. In contrast, we found that IL-10 did not contribute to the protective effect of CBLB502 inhibition of Con A hepatitis, although a previous study showed that IL-10 protects mice from Con A-induced hepatic injury. (30) It should be noted that CBLB502 also induced expression of granulocyte colony-stimulating factor, monocyte chemoattractant protein-1, and secretary interleukin-1 receptor antagonist, which have been reported to be involved in attenuating immune-mediated liver diseases. (34, 35) These data indicated that the underlying mechanisms of CBLB502 in inhibiting Con A-induced hepatitis may have more complicated aspects that have yet to be elucidated.
In summary, we demonstrated a role of TLR5 signaling in protecting against immune-mediated hepatitis. These results suggest a potential application of a TLR5-mediated mechanism in preventing the pathogenesis of immune-mediated hepatitis.
